Navigation Links
Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma
Date:7/15/2008

Study Reports 92 Percent Response Rate to Combination Treatment

FRAZER, Pa., July 15 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that in a phase 2 study published online today in the Journal of Clinical Oncology, 92 percent of patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma (NHL) responded to treatment with TREANDA(R) (bendamustine hydrochloride) for Injection plus rituximab. This combination study is one of three studies in patients with NHL that Cephalon submitted in December 2007 to the U.S. Food and Drug Administration requesting approval of TREANDA for the treatment of patients with indolent NHL who have progressed during or following treatment with rituximab or a rituximab-containing regimen. TREANDA was approved by the FDA in March 2008 for the treatment of patients with chronic lymphocytic leukemia and is not currently approved for use in NHL.

"A variety of treatment options have been employed in patients with indolent B-cell and mantle cell lymphomas, but resistance to treatment in this patient population often limits effective therapeutic options," said Dr. Charles Morris, Vice President, Worldwide Clinical Research at Cephalon. "Based on what we saw in this study, the combination of TREANDA with rituximab appears to elicit a high rate of durable responses and encouraging progression-free survival."

About the Study

In this multi-center, open-label, single arm, Phase 2 study, 66 patients with relapsed, indolent B-cell or mantle cell lymphoma without documented resistance to prior rituximab therapy were treated. Patients received rituximab 375 mg/meter squared intravenously on day one and TREANDA 90 mg/meter squared intravenously on days two and three of a 28-day cycle for up to six cycles. An additional dose of rituximab was given one week before the first cycle and four weeks after the last cycle.

Overall response rate was 92 percent with a complete respon
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
2. Complete Study Results Comparing CTIs OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
3. Results Published in the Journal Cancer Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma
4. Journal of Clinical Oncology Publishes Leukine(R) Study Demonstrating Positive Survival Outcomes in Patients with High-Risk Melanoma
5. Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)
6. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
7. The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxters Cell-Based Pandemic, Avian Flu Vaccine
8. Biopure Phase III Orthopedic Trial Results Published in Journal of Trauma
9. New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
10. Blood Spot Technology at ZRT Highlighted in March Issue of Journal of Diabetes Science & Technology - A Convenient Alternative to Serum Testing for Health Screening
11. Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)...  MedVantx, Inc., the company that has pioneered a ... the Company has completed a major expansion of its ... and the upgrade of its systems to offer a ... specialty home delivery pharmacy in Sioux Falls, ... physicians, health systems and payors novel distribution services, as ...
(Date:5/23/2013)... , May 23, 2013   BioLife Solutions , ... proprietary clinical grade hypothermic storage and ... contract aseptic media manufacturer , today announced its ... Regenerative Medicine Congress 2013 this week in ... ) Dr. Aby J. Mathew, BioLife,s Senior ...
(Date:5/23/2013)... 2013 Ranbaxy Laboratories Limited ... Daiichi Sankyo Co., Ltd. (im Weiteren ... die Maßnahmen bekannt, die Ranbaxy in ... sich der Angelegenheiten der vorhergehenden Unternehmensführung ... Daiichi Sankyo unterstützt Ranbaxy ...
Breaking Medicine Technology:MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 2MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 3BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 2BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 3Ranbaxy kündigt Verbesserungen bei Geschäftsstandards und Qualitätssicherungsinitiativen an 2
... HILL, N.C., Dec. 5, 2011   New product launches ... It is critical for organizations to balance the dueling goals ... challenge that executives face is determining how much to invest, ... of the budget for primary care launch is ...
... OrbusNeich today announced that data published in the November ... is safe when accompanied by only 10 days of dual ... 49 patients treated with Genous, no patient had died or ... myocardial infarction or angiographic evidence of stent thrombosis (ST) ascribable ...
Cached Medicine Technology:Launch Spend Insights: Companies Now Invest More in Launch Year Than in Previous 3 Ramp-Up Years Combined 2Data Published in EuroIntervention Indicate that OrbusNeich's Genous™ Stent Is Safe with Very Short-Term Dual Antiplatelet Therapy 2Data Published in EuroIntervention Indicate that OrbusNeich's Genous™ Stent Is Safe with Very Short-Term Dual Antiplatelet Therapy 3
(Date:5/23/2013)... PA (PRWEB) May 23, 2013 Pittsburgh-based ... allowing seniors to remain independent in their own homes ... Security Alert’s Director of Life Safety, recently commented on ... providers. He stated that although there are numerous ... Automated Security Alert is rare in that they are ...
(Date:5/23/2013)... Sunnyvale, CA (PRWEB) May 23, 2013 Footwear ... Dansko Vista Collection of sandals containing cork footbeds. ... Dansko has had consistently good sales for many years, and ... this spring and summer. , Dansko Shoes ... and the Vista Collection is no exception. Containing leather and ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Kitchen ... hands-on cooking classes, the most advanced culinary technique series ... from class with the knowledge of how to purchase, ... and the health benefits of organic, local ingredients. The ... which are six hours each. The next series begins ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 When Teachers ... product donations to raise funds for the Moore, OK ... dollars worth of items that could be sold for ... However, the staff at Teachers Notebook were overwhelmed by ... pledged $1000.00 worth of materials within the first 12 ...
(Date:5/23/2013)... 911 Signal USA is attending the 2013 Police Fleet ... and run through May 24, 2013. , In addition to ... emergency vehicle lights and sirens, 911 Signal USA will ... expo. , The Charger has been equipped with the best ... seen by visiting 911 Signal USA during the expo at ...
Breaking Medicine News(10 mins):Health News:Automated Security Alert's New Medical Alarm Works Even In Power Outages 2Health News:Footwear etc. Announces the New Collection of Dansko Cork Sandals 2Health News:Kitchen on Fire Launches Intermediate Cooking Series, Advancing the Culinary Skills of Experienced Home Chefs 2Health News:Kitchen on Fire Launches Intermediate Cooking Series, Advancing the Culinary Skills of Experienced Home Chefs 3Health News:Teachers Rally to Raise Funds for Moore Tornado Victims 2Health News:911 Signal USA Attends the 2013 Southwest Police Fleet Expo 2
... first Southern-style canned product ... American Heart Association, COLUMBUS, Ohio, Jan. 9 ... low fat and meatless, were the first,product line of ... savory,taste. Now, heart-healthy Sensibly Seasoned products also bear the ...
... can do quite a number on your teeth. Did ... 11 teaspoons of sugar per serving and,that most soft ... these acids can cause erosion, the loss of hard ... Terry, a Pennsylvania Dental Association (PDA),member and endodontist from ...
... WSB-TV Partner to Collect Bags at 25 Georgia Locations, ... private oncology/ hematology practice in the Southeast -- will team,up ... drive. The,event will be held at 25 GCS offices across ... p.m., "Totes 2 Tots" delivers new or nearly new ...
... lead to better prognosis, treatments, researchers say , , WEDNESDAY, ... on a handful of tiny ribonucleic acid (RNA) molecules ... travels to the lung and bone. , These "microRNAs" ... When they are missing, that allows the disease to ...
... combat mortality , , WEDNESDAY, Jan. 9 (HealthDay News) -- ... question the conventional wisdom of treating with corticosteroids, intensive ... called pentastarch. , The first study compared the ... septic shock and found no improvement in survival rates. ...
... of developmental disorder, researchers say , , WEDNESDAY, Jan. 9 (HealthDay ... risk for developing autism, a new study suggests. , The ... of the causes of a disorder that is turning out ... in its symptoms. Not only is autism complicated, its incidence ...
Cached Medicine News:Health News:Glory Foods Receives Heart Healthy Certification 2Health News:Keep a Watchful Eye on Sugary Beverage Consumption 2Health News:Georgia Cancer Specialists to Sponsor Sixth Annual 'Totes 2 Tots' Suitcase Drive for Foster Children 2Health News:Georgia Cancer Specialists to Sponsor Sixth Annual 'Totes 2 Tots' Suitcase Drive for Foster Children 3Health News:Tiny RNA Molecules Control Breast Cancer's Spread 2Health News:Tiny RNA Molecules Control Breast Cancer's Spread 3Health News:Tiny RNA Molecules Control Breast Cancer's Spread 4Health News:Standard Septic Shock Treatments Ineffective 2Health News:Standard Septic Shock Treatments Ineffective 3Health News:Standard Septic Shock Treatments Ineffective 4Health News:Chromosome Abnormalities Raise Risk for Autism 2Health News:Chromosome Abnormalities Raise Risk for Autism 3Health News:Chromosome Abnormalities Raise Risk for Autism 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: